Louisville, KY
Ketamine Therapy clinics in Louisville
Louisville has multiple clinics offering ketamine therapy, a fast growing segment for treatment resistant depression, PTSD, chronic pain, and anxiety. Kentucky permits ketamine under DEA registration; state monitoring program applies. Most Louisville clinics deliver IV ketamine infusions in a monitored clinical setting, typically across a 6 session induction protocol, followed by maintenance infusions. Spravato (esketamine), the FDA approved nasal spray for treatment resistant depression, is available in Louisville only at REMS certified clinics and is often covered by insurance when medical necessity is documented. Compounded ketamine lozenges and troches are also prescribed in Louisville, sometimes through telehealth platforms like Mindbloom, Joyous, and Innerwell, subject to Ryan Haight Act and DEA special registration considerations. Local pricing in Louisville sits in the affordable range: single IV infusions run 400 to 700 dollars, a full 6 session protocol lands at 2,400 to 4,200, and Spravato copays depend on insurance coverage. A reputable Louisville ketamine clinic will pair pharmacology with integration support, monitor vitals during infusion, and have a clear crisis and follow up plan.
Samsara Aesthetics and Wellness
- PRP Therapy
- IV Therapy
- Ketamine Therapy
- Arthritis Treatment
- Migraine Treatment
Regulatory context
A note on Kentucky's ketamine therapy rules.
Ketamine is a DEA Schedule III controlled substance, FDA-approved as a dissociative anesthetic and used off-label for treatment-resistant depression, PTSD, and chronic pain. The FDA approved esketamine (Spravato) in 2019 for treatment-resistant depression under a Risk Evaluation and Mitigation Strategy (REMS) program that requires in-office administration at certified sites. MDMA-assisted therapy remains Schedule I; the FDA issued a Complete Response Letter in August 2024 to Lykos Therapeutics on its MDMA new drug application. Psilocybin is Schedule I and holds FDA Breakthrough Therapy designation through sponsors such as Compass Pathways and Usona, but has not received FDA approval. Oregon Measure 109 (passed 2020, operational 2023) created a state psilocybin service center framework, and Colorado Proposition 122 (2022) authorized regulated healing centers.
-
Kentucky Opioid Abatement Advisory Commission / Ibogaine Proposal (2023)
Kentucky briefly considered allocating $42 million in opioid settlement funds to ibogaine research; proposal withdrawn in 2023 after public controversy. -
Kentucky Controlled Substances Act
Mirrors federal scheduling.
Kentucky enforces federal scheduling. The Kentucky Board of Medical Licensure oversees prescriber conduct with heightened scrutiny following the state's opioid crisis. DEA enforcement on ketamine clinics focuses on diversion and Ryan Haight Act telehealth rules. Kentucky's KASPER PDMP is one of the strictest in the nation.